Skip to main content
Fig. 2 | Stem Cell Research & Therapy

Fig. 2

From: Therapeutic role of uterine-derived stem cells in acute kidney injury

Fig. 2

Labeled UDCs engraft the injured kidney as demonstrated by cell count, renal DsRed mRNA expression levels, in vivo imaging system and fluorescence-activated cell sorting (FACS). a Ds-Red positive uterine-derived cells (UDCs) were injected immediately following either sham surgery or bilateral renal ischemia–reperfusion injury. DsRed positive cells were preferentially incorporated into the injured kidneys as determined by FACS. b Similarly, elevated DsRed mRNA expression levels were higher in the kidneys of the renal ischemia–reperfusion injury group compared to the sham surgery group. c DsRed positive cell counts are shown in either male or female kidneys after ischemia–reperfusion injury. DsRed cells were preferentially incorporated in males. d After unilateral ischemia–reperfusion injured, more DsRed positive cells accumulated in the injured kidney compared to the non-injured kidney. e In vivo imaging of sham group and unilateral renal ischemia–reperfusion injury. DsRed positive uterine-derived cells (UDCs, shown here in green) were preferentially incorporated into the injured kidney. f and g demonstrate fluorescence-activated cell sorting of uninjured and ischemia–reperfusion injured kidneys. f DsRed labeled uterine-derived cells (UDCs) were not incorporated into the uninjured kidney in significant numbers. g Large numbers of DsRed cells were incorporated into the injured kidney. (N = 8 per group) *denotes statistical significance (p < 0.05) sham vs UDC; male vs female and non-injured vs injured

Back to article page